Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Plant-based Mining Biotech
Azafaros aims at developing new therapeutic agents for the treatment of rare metabolic disorders.
Eeden converts end-of-life textiles into resources for new textile production.
Granite Bio is a biotechnology business developing novel antibodies to treat inflammatory, autoimmune, and fibrotic disorders.
Orbis Medicines is a novel macrocyclic chemistry and computational platform for oral macrocycle drug discovery.
Citryll is a developer of pharmaceutical drugs used to treat autoimmune and other human diseases.
Purespring Therapeutics is a gene therapy company that provides treatments for different kidney diseases.
LoQus23 is a DDF-formed company focussing on targeting DNA damage repair pathways to treat Huntington's disease.
NOVAMEAT develops cutting-edge technological solutions to feed the planet's growing population with plant-based foods.
Pheon Therapeutics is an Antibody-Drug Conjugate (ADC) specialist that creates ADCs for a variety of difficult-to-treat cancers.
Progentos Therapeutics develops an approach to treat multiple sclerosis that stimulates the body's natural repair mechanisms.
A UK-based developer of drugs to treat respiratory diseases
Rampart Bioscience develops gene medicines to provide long-lasting treatments for a wide range of diseases.
Mariana Oncology is a biotechnology research industry.
Beacon Therapeutics is a biotechnology company that develops treatments to preserve and restore vision for rare and prevalent eye diseases.
Corsera Health develops preventive RNA interference medicines that reduces cardiovascular disease risk before long-term damage occurs.
Sidera Bio harness human genetics, that helps in transformative medicines for patients.
Calluna Pharma is developing first-in-class therapies designed to defeat chronic inflammation and fibrosis at the source.
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics.
Anaveon is a developing IL-2 complexes which selectively promote effector T cell functions.
Amphista Therapeutics operates as a biopharmaceutical company.
Protego Biopharma is a biotechnology company that develops therapeutics that aim to correct diseases caused by protein misfolding.
New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.
Noema Pharma is a biotech company that develops therapies to address disabling symptoms in conditions of the brain and nervous system.
Forbion Capital Partners has invested in 122 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Forbion Capital Partners's top investment sectors include Biotechnology, Therapeutics, Medical, Health Care, Biopharma. The firm invests across 23 different industry categories.
Among tracked funding rounds, New Amsterdam Pharma received $452.6M in a Post-IPO Equity round. Forbion Capital Partners's total known invested capital is $9.0B.
Forbion Capital Partners's average investment size is $95.7M across its portfolio of 122 companies.
Recent Forbion Capital Partners portfolio additions include Genomines, Azafaros, Eeden, Granite Bio, Orbis Medicines. These companies were founded in 2020 or later.